Physician profile
Eric Glen Eliason
NPI 1760692602
$17,741.48
in general payments reported to CMS, 2019-2025
16 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $159 · 2021: $966 · 2022: $1,206 · 2023: $958 · 2024: $14K · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $1,994 · Travel and Lodging: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,860.00 |
| Food and Beverage | $1,994.00 |
| Travel and Lodging | $1,162.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11,521.82 | 2024 | |
| Abbvie INC. | $2,507.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,974.37 | 2019-2024 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $401.25 | 2022-2025 | Dupixent |
| Celgene Corporation | $333.78 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $295.14 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.07 | 2022-2024 | Trulance |
| Dova Pharmaceuticals | $122.69 | 2019 | |
| Conmed Corporation | $117.76 | 2020 | |
| Endogastric Solutions, INC | $95.35 | 2021-2022 | |
| Intuitive Surgical, INC. | $82.31 | 2021 | |
| Janssen Biotech, INC. | $37.34 | 2022-2024 | Tremfya |
| Pacira Pharmaceuticals Incorporated | $32.66 | 2024 | Exparel |
| Fujifilm Healthcare Americas Corporation | $23.93 | 2025 | |
| Braintree Laboratories, INC. | $11.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$232,833.75 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Eliason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.